Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares dropped 5% on Friday after an insider sold shares in the company. The company traded as low as $13.59 and last traded at $13.59. Approximately 2,898,374 shares traded hands during mid-day trading, a decline of 14% from the average daily volume of 3,382,050 shares. The stock had previously closed at $14.31.

Specifically, CEO John F. Crowley sold 71,735 shares of the business’s stock in a transaction on Wednesday, October 18th. The stock was sold at an average price of $14.75, for a total transaction of $1,058,091.25. Following the completion of the sale, the chief executive officer now owns 380,723 shares in the company, valued at $5,615,664.25. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO John F. Crowley sold 449,295 shares of the business’s stock in a transaction on Monday, October 16th. The stock was sold at an average price of $14.33, for a total value of $6,438,397.35. Following the sale, the chief executive officer now owns 380,723 shares of the company’s stock, valued at approximately $5,455,760.59. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 628,224 shares of company stock valued at $9,024,003. 3.40% of the stock is currently owned by corporate insiders.

A number of equities research analysts recently commented on FOLD shares. Zacks Investment Research cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. BidaskClub raised Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 19th. Robert W. Baird reaffirmed an “outperform” rating and set a $12.00 price objective on shares of Amicus Therapeutics in a research note on Friday, June 30th. Chardan Capital reaffirmed a “buy” rating and set a $16.50 price objective (down from $17.50) on shares of Amicus Therapeutics in a research note on Wednesday, September 13th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $17.00 price objective (down from $18.00) on shares of Amicus Therapeutics in a research note on Saturday, September 16th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $17.81.

The company has a 50 day moving average price of $14.45 and a 200 day moving average price of $11.05. The company’s market capitalization is $2.24 billion.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.03. The business had revenue of $7.16 million during the quarter, compared to analyst estimates of $6.96 million. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. During the same period last year, the company earned ($0.40) EPS. Equities analysts anticipate that Amicus Therapeutics, Inc. will post ($1.32) EPS for the current year.

Large investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA raised its position in Amicus Therapeutics by 3,672.2% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 68,012 shares of the biopharmaceutical company’s stock worth $685,000 after purchasing an additional 66,209 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Amicus Therapeutics by 5.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 777,146 shares of the biopharmaceutical company’s stock worth $5,541,000 after purchasing an additional 41,711 shares during the last quarter. State of Wisconsin Investment Board bought a new position in Amicus Therapeutics during the 2nd quarter worth $1,057,000. Redmile Group LLC raised its position in Amicus Therapeutics by 5.9% during the 2nd quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock worth $121,282,000 after purchasing an additional 668,080 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Amicus Therapeutics by 4.7% during the 1st quarter. Geode Capital Management LLC now owns 1,167,356 shares of the biopharmaceutical company’s stock worth $8,323,000 after purchasing an additional 52,003 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: This story was first published by Daily Political and is owned by of Daily Political. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.dailypolitical.com/2017/10/20/amicus-therapeutics-inc-fold-shares-down-5-on-insider-selling.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.